MIRROR Trial: Addition of Methotrexate to Pegloticase Is Efficacious, Safe

Doctor administers infusion therapy to patient sitting on chair, pegloticase infusion concept

Michael E. Weinblatt, MD, and colleagues are conducting the first randomized, placebo-controlled study using an immunomodulator with pegloticase to increase urate-lowering response durability. Initial findings confirm the superiority of pegloticase plus methotrexate co-therapy to pegloticase monotherapy.


Developing the First SLE Risk Prediction Model Based on Known Factors

Woman sitting on couch touching left shoulder in discomfort, joint pain from lupus SLE concept

Brigham rheumatologist and Lupus Program director Karen Costenbader, MD, MPH, helped develop a risk prediction model for systemic lupus erythematosus (SLE) incorporating genetic, environmental, and lifestyle risk factors, as well as family history. Clinicians one day may use the model to predict individuals’ SLE risks.


ECG Testing Infrequent for Patients Receiving Hydroxychloroquine or Chloroquine

Woman holding glass of water and taking white pill, hydroxychloroquine medication concept

Hydroxychloroquine and chloroquine (HCQ/CQ) have known cardiovascular adverse effects. However, Brigham and Women’s Hospital researchers found that before the COVID-19 pandemic, electrocardiograms were infrequently obtained prior to initiation of HCQ/CQ and even less often during follow-up.


TNF Inhibitors Not Superior to Triple Therapy in Reducing Vascular Inflammation in Rheumatoid Arthritis

Rendering of human heart anatomy on dark background

Researchers at Brigham and Women’s Hospital conducted the first randomized, active comparator trial to explore the effect of disease-modifying anti-rheumatic drugs on vascular inflammation in rheumatoid arthritis.


Polarization-Sensitive OCT Technically Feasible for Assessing Pre-Osteoarthritis

Female patient at ophthalmologist leaning toward machine for optical coherence tomography testing

Mass General Brigham clinicians and colleagues showed polarization-sensitive optical coherence tomography (PS-OCT) can be performed minimally invasively and report results from a pilot study that will inform a large clinical trial to determine whether PS-OCT can predict the development of osteoarthritis.


The Brigham’s Rheumatology Division Presents at ACR 2022

Headshot of Ellen M. Gravallese, MD

Members of the Division of Rheumatology, Inflammation and Immunity at Brigham and Women’s Hospital presented over 120 lectures and poster presentations at the 2022 American College of Rheumatology’s annual convergence conference. Learn more about a few of their cutting-edge presentations.


Proteomics Data Suggest Diagnostic, Therapeutic Targets for RA Patients With Interstitial Lung Disease

Doctor examing ct scan images of lungs at desk, lung disease concept

Brigham researchers recently completed the first proteomic analysis in patients with rheumatoid arthritis and interstitial lung disease (RA-ILD). They identify molecular signatures strongly associated with the presence and severity of RA-ILD and provide insight into unexplored disease pathways.


Neighborhood Vulnerability to Heat Affects Risk of Recurrent Hospitalization in Individuals With Rheumatic Conditions

Young man standing under hot bright sun and clear sky, wiping sweat from forehead

In the first study of its kind, Brigham and Women’s Hospital researchers showed that individuals with rheumatic conditions residing in neighborhoods with high social or heat vulnerability have greater odds of recurrent hospitalization than those with lower vulnerability.


Predictors of Healthcare Spending Identified in Patients With Gout Using Urate-lowering Therapy

Female patient in office signing paperwork across from doctor

Researchers at Brigham and Women’s Hospital identified three distinct groups of gout patients according to their patterns of total spending on health care. The team provides information on identifying patients with gout who could benefit from interventions to reduce long-term spending.


Understanding Calcium Pyrophosphate Deposition Disease: Q&A With Sara Tedeschi, MD, MPH

Eldery woman in wheelchair feeling arthritis discomfort in right knee

Calcium pyrophosphate deposition (CPPD) disease affects 8-10 million adults in the U.S., yet knowledge of CPPD lags far behind that of gout and other types of inflammatory arthritis. The Brigham’s Sara Tedeschi, MD, MPH, and the research team are working to understand the disease better and improve patient care.